[Newsmp] The autoimmune disease therapeutics market is fluctuating.In the interleukin inhibitors market, Skyrizi (AbbVie) surpassed Cosentyx (Novartis), and Tremfya (Johnson & Johnson) went beyond Taltz (Eli Lilly), while Dupixent is on par with Stelara (Johnson & Johnson).Rinvoq (AbbVie), a latecom

[Newsmp] As the COVID-19 pandemic is gradually heading toward the endpoint, sales of related treatments and vaccines have been affected.According to the third-quarter reports of global Big Pharma, most of the sales of COVID-19 vaccines and treatments decreased from the first or the second quarter.Am

[Newsmp] The growth of global Big Pharma has slowed amid reduced vigilance against COVID-19 since the Omicron variant, which hit the world in the first half of last year.According to the third-quarter reports of global drugmakers, 16 out of 18 companies saw their sales growth decline in the third qu

[Newsmp] The DNA of BMS is cooperation.Country manager Lee Hye-Young, who led the launch of Viatris Korea, recently moved to Bristol Myers Squibb (BMS) Korea.After graduating from Seoul National University College of Pharmacy and earning an MBA from Korea University, Lee entered the pharmaceutical i

[Newsmp] Merck Biopharma Korea has come to be the second company in Korea to launch a treatment for non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations, Tepmetko.The company explained that it has various advantages such as dosage and duration of efficacy, as well as data on liquid

[Newsmp]Vaccines that cause problems vs vaccines that solve problems.While opinions are divided over the impact of 10-valent and 13-valent pneumococcal conjugate vaccines (PCVs) on serotype 19A pneumococcal disease, a session was held to highlight the value of the 13-valent PCV based on domestic and

[Newsmp]The pre-penicillin era is on the way.Amid growing voices warning about the era of ‘antibiotic uselessness’ due to relentless evolution and rapid spread of resistance, the multidrug-resistant antifungal antibiotic Zerbaxa (Ceftolozane/Tazobactam) recently received reimbursement.It is expected

[Newsmp] The upper limit of health insurance benefits for Acelex (CrystalGenomics) and Faslodex (AstraZeneca) will be reduced by 30%.Sama Roflu (Sam-A Pharm.) and Daxas (AstraZeneca), which were expected to be lowered, will maintain their existing upper limits.The Ministry of Health and Welfare amen

[Newsmp] Alovogen and AstraZeneca had agreed not to release a generic version on condition of exclusive distribution rights for original drugs in Korea, and the Fair Trade Commission (FTC, Chairman Han Ki-jeong) imposed a corrective order and a fine.The FTC announced on the 13th that it had decided

[Newsmp] Foreign investors showed marked differences by stock in pharmaceutical stocks.Il Dong Pharmaceutical’s foreign ownership plunged by 4.57%p and Il Dong Holdings by 3.14%p, while Il-Yang Pharmaceutical, Samjin Pharmaceutical, and Bukwang Pharmaceutical also decreased by more than 1%p.Of the 3

[Newsmp] In the midst of the COVID-19 pandemic, individual investors who have been big fans of pharmaceutical stocks have lost their interest.According to the Korea Exchange, the sales of individual investors on 46 pharmaceutical stocks in the securities market were about KRW 472.6 billion, more tha

[Newsmp] Many of the pharmaceutical stocks plummeted in the third quarter, but there were also a number of stocks that entered the top stock price increase ranking.Stock prices of 50 out of 59 pharmaceutical-related stocks (including preferred stocks and holding stocks) fell in the securities market

[Newsmp] The global trend of endemic is reflected in the bio-health industry’s export performance.The bio-health industry’s exports in September fell 4.5% year-on-year to $1.328 billion, according to the Ministry of Trade, Industry and Energy.This year, exports of the bio-health industry recorded do

[Newsmp] In September, most of the pharmaceutical stocks dropped more than 10% amid repeated lethargy in the pharmaceutical index.According to the Kore Exchange, the pharmaceutical index has recently fallen to the pre-COVID-19 level, diving to the 12,000-point level.Of the 46 stocks, 41 companies fe

[Newsmp] The trade deficit of pharmaceutical products has fallen for the second consecutive month.On the other hand, diagnostic reagents that have expanded their surplus this year have decreased for two straight months.According to the Korea Customs Service, exports of pharmaceutical products (HS30)

[Newsmp] In the first half, the average sales of listed pharmaceutical and bio companies exceeded KRW 100 billion. (Closing accounts are in December, separate financial statements)According to Korean data provider FnGuide, a total of 148 pharmaceutical manufacturers posted about KRW 15.3333 trillion

[Newsmp] The debt-to-equity ratio of more than half of listed pharmaceutical companies rose in the first half. However, the average debt-to-equity ratio was still below 60%.Newsmp tallied the first half debt-to-equity ratio of 62 drug makers, whose closing accounts are in December, and found that th

[Newsmp] In August, foreign ownership of listed pharmaceutical companies showed a downward trend.According to the Korea Exchange, foreign ownership of 32 out of 46 stocks declined during this period.The range was not significant. Shin Poong Pharmaceutical was the only company whose foreign ownership

[Newsmp] In August, the number of drug patents registered by the Ministry of Food and Drug Safety (MFDS) exceeded 30.According to the MFDS information platform (https://nedrug.mfds.go.kr/), the number of patent registrations, which fell from 39 in May to 10 in June, increased to 29 in July, and rose

[Newsmp] While pharmaceutical stocks continued to struggle in August, most of the net purchases by investors were below KRW 10 billion.Institutions and foreigners largely bought Celltrion, but individuals sold heavily, showing a different trend.According to the Korea Exchange, institutional investor